A rendering of the new entrance to the Norman Regional HealthPlex is pictured. Photo Provided
Norman Regional Health Systems will soon kick off a series of five expansion and renovation projects on three different sites in an effort to expand its outreach and better serve patients.
Norman City Council voted unanimously to approve Norman Regionalâs plan to expand its HealthPlex hospital at last Tuesdayâs meeting. The first of a series of projects in the Inspire Health plan is slated to begin in May, according to Norman Regional Health System president and CEO Richie Splitt.
The plan will begin in May with the construction of Norman Regional Nine, a freestanding Emergency Department in southeast Norman at 24th Avenue SE and Highway 9. Splitt said the project is more than an emergency department staffed by physicians.
New study aims to improve anti-cancer drug response predictions across cancer types
The goal of precision oncology is to be able to tailor treatments to each individual patient based on their cancer s unique molecular fingerprints.
New technologies and large, -omics datasets are now allowing researchers to examine shared features not just within a single type of cancer -; such as breast cancer -; but to look for patterns across many types of cancer. These data offer great clues that an approach that has shown success in one type of cancer may also work well against a different type of cancer based on common underlying features.
The FDA has granted a breakthrough therapy designation to tipifarnib for use in patients with recurrent or metastatic HRAS-mutated head and neck squamous cell carcinoma.
Date Time
Share
Break Through Cancer launches collaborative model across top U.S. research institutions in pursuit of cancer cures
New foundation brings together teams from Dana-Farber Cancer Institute, the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, and the Koch Institute for Integrative Cancer Research at MIT
Break Through Cancer today announced its formal launch as a public foundation designed to find new solutions to the most intractable challenges in cancer. The foundation is being launched with an extraordinary challenge pledge of $250 million from Mr. and Mrs. William H. Goodwin, Jr. and their family, and the estate of William Hunter Goodwin III. This represents one of the largest gifts ever in support of cancer research. Led by Dr. Tyler Jacks the David H. Koch Professor of Biology and Director of the Koch Institute for Integrative Cancer Research at MIT, Break Through Cancer will fund and
email article
A treatment strategy based on manipulation of testosterone levels showed promise as a potential aid for managing castration-resistant prostate cancer (CRPC), according to a randomized proof-of-principle trial.
Following disease progression with abiraterone (Zytiga), treatment with bipolar androgen therapy (BAT) or enzalutamide (Xtandi) led to a median progression-free survival (PFS) of 5.7 months (clinical or radiographic progression). A similar proportion of patients in each treatment arm had at least a 50% reduction in baseline PSA level (PSA50 response), and overall survival (OS) did not differ significantly between the groups, reported Samuel R. Denmeade, MD, of Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins in Baltimore, and colleagues.